MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling

Area of Science:

• Nuclear medicine
• Medical physics
• Oncology

Background:

• Radiopharmaceutical therapy is expanding, but treatment planning for microscopic disease remains a challenge.
• Existing therapies lack the single-cell targeting capabilities of radiopharmaceuticals.
• Dosimetry and bioeffect modeling tools are needed to optimize radiopharmaceutical design and predict efficacy against micrometastases.

Purpose of the Study:

• To introduce MIRDcell V3, an updated software for dosimetry and bioeffect modeling in radiopharmaceutical therapy.
• To provide a tool for planning treatments targeting circulating tumor cells, disseminated tumor cells, and micrometastases.
• To enhance the design and predictive capabilities of radiopharmaceutical agents.

Main Methods:

• MIRDcell V3 employs analytic and Monte Carlo methods for dosimetry and bioeffect modeling.
• The software simulates radiolabeled cells in planar colonies and multicellular clusters.
• Advanced features include user-defined activity distributions and complex bioeffect modeling.

Main Results:

• MIRDcell V3 accurately replicates experimental responses of tumor spheroids to radiopharmaceutical treatments.
• The software demonstrates effectiveness in modeling both uniform and nonuniform activity distributions.
• Validation confirms its capacity to recapitulate published data on spheroid responses.

Conclusions:

• MIRDcell V3 is a versatile software tool for advancing radiopharmaceutical therapy.
• It serves as a valuable resource for educational purposes in nuclear medicine and oncology.
• The software facilitates the design and optimization of novel radiopharmaceutical treatments.